|
Status |
Public on Dec 22, 2016 |
Title |
Breast tumor_ Sirolimus 1 |
Sample type |
RNA |
|
|
Source name |
Primary breast tumor treated with sirolimus
|
Organism |
Homo sapiens |
Characteristics |
agent: Sirolimus tissue: Breast cancer
|
Treatment protocol |
A daily oral treatment with sirolimus (Rapamune) or control solution (DMSO) was applied (60 days).
|
Growth protocol |
Primary triple-negative breast tumor (from a BRCA1 mutation carrier) orthotopically engrafted in immunocompromised mice was monitored 2 to 3 times per week.
|
Extracted molecule |
total RNA |
Extraction protocol |
Trizol extraction of total RNA was performed according to manufacturer's instructions.
|
Label |
Biotin
|
Label protocol |
FL-Ovation cDNA Biotin Module V2 from NuGen Technologies Inc.
|
|
|
Hybridization protocol |
Affymetrix GeneChip Expression Analysis Technical Manual (P/N 702232 Rev 2).
|
Scan protocol |
Affymetrix GeneChip Expression Analysis Technical Manual (P/N 702232 Rev 2).
|
Data processing |
The data were analyzed with Partek Genomics Suite using Affymetrix default analysis settings and global scaling as normalization method.
|
|
|
Submission date |
Jul 27, 2012 |
Last update date |
Dec 23, 2016 |
Contact name |
Miguel Angel Pujana |
E-mail(s) |
[email protected]
|
Phone |
0034932607463
|
Organization name |
Institut Catala d'Oncologia IDIBELL
|
Lab |
ProCURE
|
Street address |
Gran Via 199
|
City |
Barcelona |
ZIP/Postal code |
08908 |
Country |
Spain |
|
|
Platform ID |
GPL13667 |
Series (2) |
GSE39691 |
Expression data from a triple-negative BRCA1-mutated ortho-xenograft treated with sirolimus |
GSE39694 |
Expression data from orthotopic tumors and the MCF7 and HCC1937 breast cancer cell lines |
|